One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Von Willebrand Disease Treatment Market

[ 英語タイトル ] Von Willebrand Disease Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0084129
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - CSL Behring
- Ferring Pharmaceuticals
- Grifols, S.A.
- Octapharma AG
- Pfizer, Inc.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Ltd

[Report Description]

According to the World Federation of Hemophilia, Von Willebrand disease is a very common bleeding defect. People suffering from the Von Willebrand disease have a defect in the protein present in their blood, known as the Von Willebrand factor. The Von Willebrand factor helps the cells present in the blood vessel called platelets, to form a clot to control and stop bleeding.

Von Willebrand disease is a frequent inherited disorder that affects both sexes. The growing healthcare expenditure and rising number of assistance programs for patients who need treatment of von Willebrand disease is expected to drive the von Willebrand disease treatment market. However, due to the lack of awareness about the disease and high cost of the treatment is among the major barrier for the growth of this market over the forecast period.

Key Market Trends

Desmopressin Segment is Expected to Register a Significant Growth in the Forecast Years

By treatment type, the market has been segmented into Desmopressin, Replacement Therapies, Clot-stabilizing Medications, and others. Desmopressin stimulates the release of VWF from cells, which also increases FVIII. This is considered to be the most preferred treatment option for patients with type 1, who account for approximately 70% to 80% of cases.

Type 1 and some subtypes of type 2 von willebrand disease have more effective results with desmopressin as compared to the other types and thus it is expected to grow during the forecast period. In addition, growing health spending and large patient pool also contributes to the growth of von willebrand disease treatment market.

North America Leads the Von Willebrand Disease Treatment Market

North America is found leading the market owing to the upsurge in the demand for progressive treatment options, early adoption of new technologies and an increase in patient assistance programs. According to the National Hemophilia Foundation, VWD is the most common bleeding disorder, affecting up to 1% of the US population.

Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool, emerging economies, and a rise in the collaboration of domestic and international companies in these regions, thus driving this market.

Competitive Landscape

The von willebrand disease treatment market is competitive and many of the global players are into the market. For instance - Bayer AG, CSL Behring, Ferring Pharmaceuticals, Grifols, Octapharma AG, Pfizer, Sanofi, Sun Pharmaceutical and Takeda are providing these products across the globe.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Patient Assistance Programs
4.2.2 Growing Healthcare Expenditure
4.3 Market Restraints
4.3.1 Lack of Awareness
4.3.2 High Cost of Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Disease Type
5.1.1 Type 1
5.1.2 Type 2
5.1.3 Type 3
5.1.4 Acquired VWD
5.2 By Treatment Type
5.2.1 Desmopressin
5.2.2 Replacement Therapies
5.2.3 Clot-stabilizing Medications
5.2.4 Others
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Injection
5.3.3 Other
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 CSL Behring
6.1.2 Ferring Pharmaceuticals
6.1.3 Grifols, S.A.
6.1.4 Octapharma AG
6.1.5 Pfizer, Inc.
6.1.6 Sanofi S.A.
6.1.7 Sun Pharmaceutical Industries Ltd.
6.1.8 Takeda Pharmaceutical Company Ltd




Recommended reports